Somatostatin receptors in GtoPdb v.2023.1

  • Corinne Bosquet University Toulouse III Paul Sabatier https://orcid.org/0000-0002-2501-0593
  • Justo P. Castaño University of Cordoba
  • Zsolt Csaba Université Paris Diderot
  • Micheal Culler Ipsen
  • Pascal Dournaud Université Paris Diderot
  • Jacques Epelbaum INSERM- UNIVERSITE PARIS DESCARTES UMR. 549
  • Wasyl Feniuk University of Cambridge
  • Anthony Harmar University of Edinburgh
  • Rebecca Hills University of Edinburgh
  • Leo Hofland Erasmus Medical Center
  • Daniel Hoyer University of Melbourne https://orcid.org/0000-0002-1405-7089
  • Patrick P. A. Humphrey University of Cambridge
  • Hans-Jürgen Kreienkamp University Medical Center Hamburg-Eppendorf
  • Amelie Lupp Friedrich-Schiller-University
  • Shlomo Melmed Cedars-Sinai Medical Center
  • Wolfgang Meyerhof Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke
  • Anne-Marie O'Carroll University of Bristol https://orcid.org/0000-0001-5255-8506
  • Yogesh C. Patel McGill University
  • Terry Reisine ActiveSite Biotech
  • Jean-Claude Reubi University of Berne
  • Marcus Schindler Boehringer Ingelheim Pharma
  • Herbert Schmid Novartis Institutes for Biomedical Research
  • Agnes Schonbrunn University of Texas
  • Stefan Schulz Friedrich Schiller University
  • John E. Taylor Biomeasure Inc
  • Giovanni Tulipano University of Brescia
  • Annamaria Vezzani Istituto di Ricerche Farmacologiche Mario Negri
  • Hans-Jürgen Wester Technische Universität München

Abstract


Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (SST1-SST5; nomenclature as agreed by the NC-IUPHAR Subcommittee on Somatostatin Receptors [98]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of secretion of many hormones. Endogenous ligands for these receptors are somatostatin-14 (SRIF-14) and somatostatin-28 (SRIF-28). cortistatin-14 has also been suggested to be an endogenous ligand for somatostatin receptors [61].

Published
26-Apr-2023
How to Cite
Bosquet, C., Castaño, J. P., Csaba, Z., Culler, M., Dournaud, P., Epelbaum, J., Feniuk, W., Harmar, A., Hills, R., Hofland, L., Hoyer, D., Humphrey, P. P. A., Kreienkamp, H.-J., Lupp, A., Melmed, S., Meyerhof, W., O’Carroll, A.-M., Patel, Y. C., Reisine, T., Reubi, J.-C., Schindler, M., Schmid, H., Schonbrunn, A., Schulz, S., Taylor, J. E., Tulipano, G., Vezzani, A. and Wester, H.-J. (2023) “Somatostatin receptors in GtoPdb v.2023.1”, IUPHAR/BPS Guide to Pharmacology CITE, 2023(1). doi: 10.2218/gtopdb/F61/2023.1.
Section
Summaries